Mechanisms of disease: Histone modifications in Huntington's disease (Q34560517)

3 August 2017

1 reference

title

Mechanisms of disease: Histone modifications in Huntington's disease (English)

1 reference

3 August 2017

0 references

Ghazaleh Sadri-Vakili

series ordinal

1

object named as

Ghazaleh Sadri-Vakili

1 reference

3 August 2017

Jang-Ho J Cha

2

1 reference

3 August 2017

publication date

1 June 2006

1 reference

Nature Clinical Practice Neurology

3 August 2017

published in

1 reference

3 August 2017

volume

2

1 reference

3 August 2017

issue

6

1 reference

3 August 2017

page(s)

330-338

1 reference

Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Trinucleotide repeat length instability and age of onset in Huntington's disease

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Trinucleotide repeats in neurogenetic disorders

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Excitotoxic injury of the neostriatum: a model for Huntington's disease

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Mitochondrial dysfunction in neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Calcium-dependent cleavage of endogenous wild-type huntingtin in primary cortical neurons

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Autophagy regulates the processing of amino terminal huntingtin fragments

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Impairment of the ubiquitin-proteasome system by protein aggregation

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Polyglutamine fibrillogenesis: the pathway unfolds

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Progressive disruption of cellular protein folding in models of polyglutamine diseases.

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy.

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Transcriptional dysregulation in Huntington's disease

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Transcriptional abnormalities in Huntington disease

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Transcriptional activation modulated by homopolymeric glutamine and proline stretches

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Trinucleotide repeats and long homopeptides in genes and proteins associated with nervous system disease and development

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease.

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Decreased expression of striatal signaling genes in a mouse model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A.

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

The language of covalent histone modifications

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Histone deacetylase inhibitors as new cancer drugs

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Chromatin remodeling and cancer

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Histone Acetylation and Gastrointestinal Carcinogenesis

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Histone deacetylase inhibitors in cancer treatment

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Histone deacetylase inhibitors reduce polyglutamine toxicity

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Altered transcription in yeast expressing expanded polyglutamine

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Ultrastructure of nuclear aggregates formed by expressing an expanded polyglutamine

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

REELIN and schizophrenia: a disease at the interface of the genome and the epigenome

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Histone deacetylase inhibitors: understanding a new wave of anticancer agents

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

β-adrenergic receptor induction in HeLa cells: Synergistic effect of 5-azacytidine and butyrate

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

https://api.crossref.org/works/10.1038/NCPNEURO0199

1 reference

7 January 2021

Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia

1 reference

https://api.crossref.org/works/10.1038/NCPNEURO0199

7 January 2021

Identifiers

DOI

10.1038/NCPNEURO0199

1 reference

3 August 2017

1 reference